Start with a free account for 3 free CME credits. Already a subscriber? Sign in.

Paper Chase 1: Empagliflozin and Mortality in Type 2 Diabetic Patients

Andrew Buelt, DO and Joe Weatherly, DO
00:00
07:15
Sign in or subscribe to listen

No me gusta!

The flash player was unable to start. If you have a flash blocker then try unblocking the flash content - it should be visible below.

Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.

 

To view chapter written summaries, you need to subscribe.

Sign up today for full access to all episodes.

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To download files, you need to subscribe.

Sign up today for full access to all episodes.
Palliative Cerumen Emergencies Full episode audio for MD edition 194:36 min - 91 MB - M4AHippo Primary Care RAP January 2016 Summary 1 MB - PDF

To earn CME for this chapter, you need to subscribe.

Sign up today for full access to all episodes and earn CME.

0.25 Free AMA PRA Category 1 Credits™ certified by Hippo Education or 0.25 Free prescribed credits by the American Academy of Family Physicians

  1. Complete Quiz
  2. Complete Evaluation
  3. Print Certificate

3.25 AMA PRA Category 1 Credits™ certified by Hippo Education or 3.25 prescribed credits by the American Academy of Family Physicians

  1. Complete Quiz
  2. Complete Evaluation
  3. Print Certificate